Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer (Q36723147)

15 August 2017

1 reference

title

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer (English)

1 reference

15 August 2017

1 reference

2

John C Bell

1 reference

15 August 2017

Anthony T Power

1

1 reference

15 August 2017

30 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

15

1 reference

15 August 2017

4

1 reference

15 August 2017

660-665

1 reference

[Discovery of the first virus, the tobacco mosaic virus: 1892 or 1898?].

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Recent progress in the battle between oncolytic viruses and tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

The complement response against an oncolytic virus is species-specific in its activation pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Humoral immune responses against minute virus of mice vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Adoptive-cell-transfer therapy for the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

In vivo tracking of tumor-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Synergistic antitumor effects of immune cell-viral biotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Marrow stromal cells as stem cells for nonhematopoietic tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Origins of circulating endothelial cells and endothelial outgrowth from blood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Dissemination and growth of cancer cells in metastatic sites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

The plasticity of dendritic cell responses to pathogens and their components

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Preferential targeting of vesicular stomatitis virus to breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Rescue and propagation of fully retargeted oncolytic measles viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

An oncolytic measles virus engineered to enter cells through the CD20 antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300098

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300098

1 reference

15 August 2017

1 reference

PubMed ID

17264852